10/07/2024
Major depression disorder study thanks to Laser Therapy U gives hope for those struggling with depression and anxiety.
๐๐ซ๐๐ง๐ฌ๐๐ซ๐๐ง๐ข๐๐ฅ ๐๐ก๐จ๐ญ๐จ๐๐ข๐จ๐ฆ๐จ๐๐ฎ๐ฅ๐๐ญ๐ข๐จ๐ง ๐
๐จ๐ซ ๐๐ก๐ ๐๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ ๐๐ ๐๐๐ฉ๐ซ๐๐ฌ๐ฌ๐ข๐จ๐ง: ๐๐ฎ๐ซ๐ซ๐๐ง๐ญ ๐๐๐ซ๐ฌ๐ฉ๐๐๐ญ๐ข๐ฏ๐๐ฌ
Askalsky & Iosifescu
Major depressive disorder (MDD) is a prevalent condition associated with high rates of disability, as well as suicidal ideation and behavior. Current treatments for MDD have significant limitations in efficacy and side effect burden. FDA-approved devices for MDD are burdensome (due to repeated in-office procedures) and are most suitable for severely ill subjects. There is a critical need for device-based treatments in MDD that are efficacious, well-tolerated, and easy to use. In this paper, we review a novel neuromodulation strategy, transcranial photobiomodulation (t-PBM) with near-infrared light (NIR). The scope of our review includes the known biological mechanisms of t-PBM, as well as its efficacy in animal models of depression and in patients with MDD. Theoretically, t-PBM penetrates into the cerebral cortex, stimulating the mitochondrial respiratory chain, and also significantly increases cerebral blood flow. Animal and human studies, using a variety of t-PBM settings and experimental models, suggest that t-PBM may have significant efficacy and good tolerability in MDD. In aggregate, these data support the need for large confirmatory studies for t-PBM as a novel, likely safe, and easy-to-administer antidepressant treatment.
FULL PAPER:https://www.tandfonline.com/doi/full/10.2147/NDT.S188906